- JX Luxventure Limited (NASDAQ:JXJT) shares are trading lower on Tuesday for no specific company-related updates.
- On April 28, 2023, JX Luxventure disclosed receiving a Nasdaq delisting notice for failing to maintain the minimum bid price of $1.00 per share. The regulator granted the company time till May 4 to regain compliance with the norms.
- On October 24, 2022, JX Luxventure received its first letter from Nasdaq.
- On April 26, 2023, the company requested a hearing before the Nasdaq Hearings Panel to present its plan to regain compliance with the requirement. On April 27, JX Luxventure received a letter from Nasdaq granting the appeal and scheduling the hearing for May 25.
- On April 26, 2023, JX Luxventure effected a one-for-ten (1-for-10) reverse stock split of its common stock on the Nasdaq. It also plans to present its financial data, including stockholders’ equity, in its annual report on Form 20-F before the hearing to demonstrate its compliance with other continued listing requirements for the Nasdaq.
- JX Luxventure delivers comprehensive product solutions to global high-net-worth families serviced by its customers, with business segments covering tourism, duty-free cross-border merchandise, and technology solutions.
- Price Action: JXJT shares traded lower by 36.90% at $7.51 on the last check Tuesday.
Immutep Earlier Announced Final Data in 2 nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
– Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announces positive final data from Part B of the TACTI-002 Phase II trial in 2 nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO's European Lung Cancer Congress (ELCC) 2023.
